AdipoGen Life Sciences

Bortezomib

CHF 70.00

In stock

AG-CR1-3602-M0055 mgCHF 70.00

AG-CR1-3602-M02525 mgCHF 280.00

More Information
Product Details
Synonyms	PS-341; LDP-341; MLM-341; MG-341; NSC-681239; Proteasome Inhibitor
Product Type	Chemical
Properties
Formula	C₁₉H₂₅BN₄O₄
MW	384.2
CAS	179324-69-7
RTECS	ED7771666
Purity Chemicals	≥97% (NMR)
Appearance	White solid.
Solubility	Soluble in DMSO, ethanol or methanol. Slightly soluble in water.
InChi Key	GXJABQQUPOEUTA-RDJZCZTQSA-N
Smiles	CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=NC=CN=C1)B(O)O
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Protect from light.
Use/Stability	Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

Highly potent, selective and reversible cell permeable inhibitor of the proteasome. Inhibits the chymotrypsin-like and caspase-like peptidase activity of the proteasome.
Calpain and cathepsin inhibitor.
Autophagy activator.
Anticancer compound. Inhibits proliferation and migration of several tumor cell lines with nanomolar potency.
Apoptosis inducer.

Product References

Proteasome inhibitors: a novel class of potent and effective antitumor agents: J. Adams, et al.; Cancer Res. 59, 2615 (1999)
Development of the proteasome inhibitor Velcade (Bortezomib): J. Adams & M. Kauffmann; Cancer Invest. 22, 304 (2004)
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells: S.T. Nawrocki, et al.; Cancer Res. 65, 11510 (2005)
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib: D. Chauhan, et al.; Cancer Cell 8, 407 (2005)
Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate: A.F. Kisselev, et al.; J. Biol. Chem. 281, 8582 (2006)
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro: T.M. Horton, et al.; Cancer Chemother. Pharmacol. 58, 13 (2006)
Bortezomib as an antitumor agent: A.M. Roccaro, et al.; Curr. Pharm. Biotechnol. 7, 441 (2006) (Review)
Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib: A. Kardosh, et al.; Cancer Res. 68, 843 (2008)
Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation: C. Li, et al.; J. Biol. Chem. 285, 16096 (2010)
Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis: M. Hirai, et al.; Blood 117, 500 (2011)
Bortezomib, a proteasome inhibitor, attenuates angiotensin II-induced hypertension and aortic remodeling in rats: S. Li, et al; PLoS One 8, e78564 (2013)
Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells: H. Min, et al.; Cancer Chemother. Pharmacol. 74, 167 (2014)
Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis: A. Ghobadi, et al.; Blood 124, 2752 (2014)
Bortezomib inhibits C2C12 growth by inducing cell cycle arrest and apoptosis: S.S. Xing, et al.; BBRC 445, 375 (2014)
Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2: Z. Wang, et al.; Int. J. Oncol. 45, 1469 (2014)
Efficient apoptosis and necrosis induction by proteasome inhibitor: bortezomib in the DLD-1 human colon cancer cell line: R. Krętowski, et al.; Mol. Cell Biochem. 398, 165 (2015)
Live cell, image-based high-throughput screen to quantitate p53 stabilization and viability in human papillomavirus positive cancer cells: G. Martinez-Noel, et al.; Virology 560, 96 (2021)

Call	+41 61 926 6040
Fax	+41 61 926 6049